Chemotherapy with or without KRAS inhibitor for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic cancer must have spread to other parts of your body (metastatic)
- Your cancer must have a specific genetic mutation called KRAS G12D (confirmed by biopsy or cell sampling)
- You have not received any chemotherapy or other cancer treatments for your metastatic disease
- You are in good enough health to tolerate treatment (ECOG performance status 0–1, meaning you can do most daily activities)
- Your heart, liver, and kidneys are working well enough for treatment
- You do not have cancer that has spread to your brain, or it is not currently active
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This study tests a new targeted drug, GFH375, against standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the new drug works better and has fewer side effects.
This trial compares a new targeted pill (DN022150) with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12D gene change. It aims to see if the new drug works better at shrinking tumors and improving survival.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.